Efficacy of FLAG Regimen for the Treatment of Patients With AML

Tianjin Medical University

Status: Unknown

Conditions: Leukemia, Myeloid, Acute; Leukemia; Leukemia, Myeloid

Study type: Observational

Funder types: Other

Identifiers

NCT03600558

Handong

Details and patient eligibility

About

The long-term efficacy of chemotherapy in patients with acute myeloid leukemia (AML) has been significantly improved in recent years. The combination of anthracycline plus cytarabine (Ara-C) has been a standard induction regimen for patients with AML. However, the optimal consolidation therapy after induction chemotherapy has not reached a consensus. The FLAG regimen consisting of fludarabine and high-dose cytarabine combined with G-CSF which is one of the first-line consolidation treatment options for relapsed and refractory AML. This study conducted a retrospective analysis of the intensive treatment of AML with the FLAG regimen from January 2007 to May 2018 in our hospital to evaluate the efficacy of the FLAG regimen. To provide the basis for the choice and timing of treatment for patients with AML treated with the FLAG regimen.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient more than 18 year old
• De novo or secondary leukemia.
• Treated with FLAG regimen

Exclusion criteria

• Acute promyelocytic leukemia (APL)